NCAN Genotype

Most people think of liver disease and brain health as two separate stories. The NCAN gene is one of the rare places where they overlap. Variants in this single gene have been linked to fatty liver, liver cancer in heavy drinkers, lipid changes, bipolar disorder, schizophrenia, and depression.

Testing NCAN gives you a one-time read on whether you carry these inherited variants. The result will not change over your lifetime, but knowing it can shape how aggressively you screen for fatty liver, watch your lipid panel, or pay attention to family history of mood disorders.

What NCAN Actually Does

NCAN (neurocan) is the instruction manual for a protein called neurocan. Neurocan is part of the scaffolding between brain cells, helping them stick together, move, and form the connections that store memory and shape mood. It is concentrated in the brain (where it is typically described as CNS-specific), though a single study has also reported neurocan expression in human liver tissue.

That potential dual residency, brain and possibly liver, has been used to help explain why a single gene shows up in such different places: psychiatric conditions on one hand, fatty liver and lipid disorders on the other. The liver expression finding, however, comes from a single report and is not yet a well-established feature of the protein.

Liver Fat and Fatty Liver Disease

A large genome-wide analysis identified a variant in or near NCAN called rs2228603 (also written as P92S) as a genome-wide significant signal for fat building up in the liver on CT scans, and for biopsy-confirmed nonalcoholic fatty liver disease (NAFLD) in people of European ancestry. The same study tied the variant to changes in blood lipids and other metabolic traits.

The picture is not the same in every population. Studies in Chinese, Taiwanese, and Uyghur cohorts found that NCAN rs2228603 was not associated with NAFLD risk, though it sometimes tracked with HDL cholesterol, ALT (a liver enzyme), or alkaline phosphatase (another liver enzyme). If your ancestry is East Asian, the NCAN signal for fatty liver is much weaker, and other genes like PNPLA3 carry more weight.

There is an important wrinkle here. Later work showed that a different nearby variant, TM6SF2 rs58542926, explains much of what was originally attributed to NCAN. The minor allele of TM6SF2 raises the risk of NAFLD and fibrosis progression. NCAN and TM6SF2 sit next to each other on chromosome 19, and disentangling the two has reshaped how researchers read the NAFLD signal in this region. More recent large-scale NAFLD genome-wide studies identify TM6SF2, not NCAN, as the causal gene at this locus.

Liver Cancer in Alcoholic Liver Disease

If you drink heavily or already have alcoholic liver disease, NCAN matters more directly. In a study of about 1,626 people, the T allele of rs2228603 was significantly enriched in those who developed hepatocellular carcinoma (liver cancer) on top of alcoholic liver disease, with odds ratios in the range of about 1.8 to 2.5 compared to alcoholic cirrhosis without cancer. The same variant did not raise liver cancer risk in people whose liver disease came from hepatitis C.

One important caveat: a larger 2022 genome-wide study of alcohol-related liver cancer pointed to TM6SF2 rs58542926, not NCAN rs2228603, as the strongest signal at this chromosome 19 locus. The same TM6SF2 confound that complicates the NAFLD finding may also apply here, so the NCAN-specific contribution to alcohol-related liver cancer is less clear than it once appeared.

What this means for you: this is a context-specific risk. The variant does not automatically mean you will get liver cancer, but if you carry it AND drink heavily, the combination warrants taking the alcohol exposure more seriously and getting closer liver surveillance.

Lipids and Cardiometabolic Risk

Variants in and near NCAN, including rs2228603 and rs16996148, have been linked to LDL cholesterol and triglyceride levels in some populations, with effects that often differ by sex and ethnicity. People carrying certain genotypes show higher HDL or shifted alkaline phosphatase. A systematic review listed NCAN as one of 24 genes that appear to sit at the crossroads of mood disorders and cardiometabolic disease.

Bipolar Disorder, Schizophrenia, and Depression

NCAN's other major signal is psychiatric. A different variant, rs1064395, is a genome-wide significant risk factor for bipolar disorder, with a combined odds ratio of about 1.17 across the original discovery and replication samples. The same risk allele was over-represented in people with schizophrenia compared to controls, and has been associated with reduced gray matter in the amygdala and hippocampus, two brain regions central to emotion processing, in both healthy people and those with major depression.

When researchers looked at which symptoms tracked most tightly with the NCAN risk allele, the strongest signal was for mania and overactivity, the high-energy, impulsive end of the bipolar spectrum. This pattern showed up not just in bipolar but also in schizophrenia and depression.

These are modest-effect variants. Carrying the risk allele does not mean you will develop a psychiatric condition. It is one inherited factor among many, and most carriers never develop bipolar disorder or schizophrenia. But if you already have a family history, the genetic background can help explain why.

Reconciling the Brain and Liver Signals

It is reasonable to wonder how a single gene ends up tied to such different problems. The simplest framing: NCAN is not a "good number, bad number" gene. It is a pleiotropic gene, meaning different variants in different parts of the gene affect different tissues. The liver-fat signal (rs2228603) and the bipolar signal (rs1064395) are separate variants pointing to separate biology. Carrying one does not mean you carry the other.

Other Conditions Linked to NCAN

A rare missense variant in NCAN, rs146011974 (Ala1039Thr), co-segregated with developmental dyslexia in a single Finnish family pedigree, and rs1064395 has been tied to a higher burden of cortical lesions in post-mortem brain tissue from people with multiple sclerosis. These are smaller signals than the bipolar and liver findings, but they fit the broader picture of NCAN as a gene that shapes brain extracellular structure.

One-Time Result, Lifetime Use

NCAN is a germline genotype. The DNA sequence you inherited at birth is what the test reports, and it will be the same if you redrew the test next year or in 20 years. There is no "trend" to track for NCAN itself.

What does need ongoing tracking is the phenotype: the actual liver, metabolic, and mental health markers that the genotype puts you at higher inherited risk for. If you carry a NAFLD-associated variant, ALT, AST, GGT (gamma-glutamyl transferase, a liver enzyme), and lipid panels deserve more attention, ideally annually. If you carry the rs1064395 psychiatric risk allele, family history conversations and mental health awareness matter more than retesting the SNP.

What to Do With an Out-of-Pattern Result

If your NCAN result flags a risk variant, the next steps are about phenotype monitoring and lifestyle decisions, not retesting the gene. For the rs2228603 NAFLD/liver cancer signal, consider ordering a comprehensive liver panel, lipid panel with ApoB, and discussing liver imaging (ultrasound or FibroScan) with your physician, especially if you drink alcohol regularly. For the rs1064395 psychiatric signal, the result is best read alongside family history. If bipolar disorder or schizophrenia runs in your family and you carry the risk allele, a conversation with a mental health clinician about what to watch for is more useful than any followup lab.

A genetic counselor can be valuable for interpreting the result in the context of your full family history, especially because NCAN sits next to TM6SF2 and the two are often discussed together in liver research.

When Results Can Be Misleading

Genetic test results carry their own kinds of confounders, different from blood markers. The most important ones:

• Variant panel coverage: the assay only checks the specific variants it was designed to detect. A "negative" result rules out those specific SNPs, not every possible NCAN variation.
• Ancestry differences: the NCAN rs2228603 signal for fatty liver is strong in European populations but weak or absent in East Asian populations. The clinical meaning of your result depends partly on your ancestry.
• The TM6SF2 confound: because TM6SF2 sits next to NCAN and shares many of the same signals for liver fat and alcohol-related liver cancer, earlier reports attributing risk to NCAN may actually reflect TM6SF2. Look at both if available.
• Single-SNP interpretation: NCAN variants are modest-effect risk factors. A risk allele does not mean disease, and a non-risk allele does not mean immunity. Other genes and lifestyle factors usually matter more for actual outcomes.